What's the difference between Foundayo and Wegovy?

Foundayo is a weight loss medication composed of tirzepatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, developed by Eli Lilly and Company. It has been approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adults with obesity (BMI ≥ 30) or in overweight adults (BMI ≥ 27) with at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol [1].

Wegovy, on the other hand, is a similar medication also developed by Eli Lilly and Company. It is also a GLP-1 receptor agonist, but it is specifically indicated for chronic weight management in adults with obesity or overweight [2]. Wegovy was initially approved as a type 2 diabetes treatment but later received approval for weight management.

While both medications are used for weight loss, the key difference between Foundayo and Wegovy lies in their dosing frequencies and potential use in non-obese patients. Foundayo is available in a weekly dosing option and, per the FDA, is approved for adults with obesity, regardless of whether they have any comorbidities [1]. Wegovy is currently only approved as a weekly dosing option and requires patients to have at least one weight-related condition for approval [2].

As per DrugPatentWatch.com, both medications are still under patent, and their prices may vary on the market [3, DrugPatentWatch.com]. It's essential to note that Wegovy requires a prescription and has associated costs, while Foundayo also needs a prescription and has a specific patient selection requirement [1].

Sources:
[1] Eli Lilly and Company. (2023). Tirzepatide prescribing information.
[2] Eli Lilly and Company. (2021). Semaglutide (Wegovy) prescribing information.
[3] DrugPatentWatch.com.